PT - JOURNAL ARTICLE AU - Stoliaroff-Pepin, Anna AU - Peine, Caroline AU - Herath, Tim AU - Lachmann, Johannes AU - Hellenbrand, Wiebke AU - Perriat, Delphine AU - Dörre, Achim AU - Nitsche, Andreas AU - Michel, Janine AU - Grossegesse, Marica AU - Hofmann, Natalie AU - Rinner, Thomas AU - Kohl, Claudia AU - Brinkmann, Annika AU - Meyer, Tanja AU - Stern, Daniel AU - Treindl, Fridolin AU - Dorner, Brigitte G. AU - Hein, Sascha AU - Werel, Laura AU - Hildt, Eberhard AU - Gläser, Sven AU - Schühlen, Helmut AU - Isner, Caroline AU - Peric, Alexander AU - Ghouzi, Ammar AU - Reichardt, Annette AU - Janneck, Matthias AU - Lock, Guntram AU - Huster, Dominik AU - Grünewald, Thomas AU - Schaade, Lars AU - Wichmann, Ole AU - Harder, Thomas TI - Vaccine effectiveness against severe COVID-19 during the Omicron wave in Germany: Results from the COViK study AID - 10.1101/2023.01.09.23284327 DP - 2023 Jan 01 TA - medRxiv PG - 2023.01.09.23284327 4099 - http://medrxiv.org/content/early/2023/01/09/2023.01.09.23284327.short 4100 - http://medrxiv.org/content/early/2023/01/09/2023.01.09.23284327.full AB - Purpose COViK - a prospective hospital-based multicenter case-control study in Germany - aims to assess the effectiveness of COVID-19 vaccines against severe disease. Here, we report vaccine effectiveness (VE) against COVID-19-caused hospitalization and intensive care treatment during the Omicron wave.Methods We analyzed data from 276 cases with COVID-19 and 494 control patients recruited in 13 hospitals from 1 December 2021 to 5 September 2022. We calculated crude and confounder-adjusted VE estimates.Results 21% of cases (57/276) were not vaccinated, compared to 5% of controls (26/494; p < 0.001). Confounder-adjusted VE against COVID-19-caused hospitalization was 55.4% (95% CI: 12-78%), 81.5% (95% CI: 68-90%) and 95.6% (95%CI: 88-99%) after two, three and four vaccine doses, respectively. VE against hospitalization due to COVID-19 remained stable up to one year after three vaccine doses.Conclusion Three vaccine doses remained highly effective in preventing severe disease and this protection was sustained; a fourth dose further increased protection.Ethical review and trial registration The study was approved by the Ethics Committee of the Charité Universitätsmedizin, Berlin (EA1/063/21) and was registered at “Deutsches Register Klinischer Studien” (DRKS00025004).Potential conflicts of interest S. G. received payment/honoraria from Astra Zeneca, Boehringer Ingelheim, Roche Pharma, Novartis and Berlin Chemie, this had no influence on this work; all other authors reported no conflicts of interest.Competing Interest StatementS. G. received payment/honoraria from Astra Zeneca, Boehringer Ingelheim, Roche Pharma, Novartis and Berlin Chemie, this had no influence on this work; all other authors reported no conflicts of interest.Clinical Protocols https://drks.de/search/de/trial/DRKS00025004 Funding StatementThis study is funded by the German Federal Ministry of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Ethics Committee of the Charite Universitaetsmedizin, Campus Charite Mitte, Chariteplatz 1, 10117 Berlin. Ref.no: EA1/063/21.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors